Company Overview
Avid Bioservices, Inc. (NASDAQ: CDMO) is a specialized contract development and manufacturing organization (CDMO) focused on biologics. The company is dedicated to enhancing patient outcomes by delivering high-quality services to biotechnology and pharmaceutical firms. With over 30 years of experience, Avid has established itself as a reliable partner in the development and manufacturing of biologic therapies.
Impressive First Quarter Results
In its recent financial report for the first quarter, Avid announced a remarkable revenue of $40.2 million. This reflects a 6% increase compared to the same quarter last year, which saw revenues of $37.7 million. The growth in revenue was largely fueled by improved process development services as the company welcomed new business opportunities.
Building Momentum with New Business
During this quarter, Avid secured $66 million in net new business, leading to a substantial backlog of $219 million. This represents a 16% increase from the $189 million backlog recorded at the same time last year. Nick Green, the company’s President and CEO, emphasized that a variety of projects, spanning both early-phase and late-stage programs, have significantly contributed to this positive trend. Avid is optimistic about converting a significant portion of this backlog into revenue in the upcoming fiscal quarters.
Investment in Growth
Avid's continuous investments in its infrastructure and capabilities have been vital to its success. The company has expanded its operational capacity to meet the demands of both large pharmaceutical companies and smaller biotech firms. This strategic growth initiative supports Avid’s ongoing efforts to diversify its customer base and expand its project pipeline. The strong results from this quarter indicate a promising trajectory for the company's future.
Financial Highlights
In terms of financial performance, Avid reported a gross profit of $5.7 million for the quarter ending July 31, 2024, resulting in a gross margin of 14%. This is a notable increase from the previous year's gross profit of $4.1 million and a gross margin of 11%. Operating expenses rose by 30% to $8.2 million, primarily due to increased compensation and consulting costs. Additionally, Avid reported a net loss of $5.5 million, or $0.09 per share, reflecting strategic investments aimed at fostering future growth.
Future Projections
Avid has maintained its revenue guidance for fiscal 2025, projecting between $160 million and $168 million. As new business opportunities continue to emerge, Avid aims to maximize its remaining capacity while leveraging its strong industry reputation. This approach is expected to improve margins and further stimulate growth in the forthcoming quarters.
Recent Developments
Throughout the reported quarter, Avid’s commercial team achieved significant contract signings, focusing on building a broader revenue base with larger pharmaceutical clients. The company's commitment to expanding its client base underscores its dedication to sustained growth and operational excellence. With additional large pharmaceutical clients joining its portfolio, Avid is strategically positioned for future success.
Contact Information
For more information or investor inquiries, Avid has provided the following contacts:
Stephanie Diaz (Investors) Vida Strategic Partners 415-675-7401 sdiaz@vidasp.com Tim Brons (Media) Vida Strategic Partners 415-675-7402 tbrons@vidasp.com
Frequently Asked Questions
What are Avid Bioservices' recent financial results?
Avid reported a revenue of $40.2 million for the first quarter, reflecting a 6% growth year-over-year, driven by strong demand for process development services.
How much new business did Avid Bioservices secure?
The company secured $66 million in net new business, resulting in a total backlog of $219 million, which is a 16% increase from last year's backlog.
What profits did Avid Bioservices achieve in the latest quarter?
Avid achieved a gross profit of $5.7 million, leading to a gross margin of 14%, which is an improvement from 11% in the previous year.
What is the future revenue guidance for Avid?
Avid has confirmed its revenue guidance for fiscal 2025, projecting between $160 million and $168 million.
Who can I contact for more information about Avid Bioservices?
For investor inquiries, please reach out to Stephanie Diaz at Vida Strategic Partners. For media-related questions, contact Tim Brons at the same firm.
